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The spectacular fall in cardiovascular mortality that has oc-
curred in most western societies in the past 40 years has
contributed significantly to a steady rise in life expectancy.
The Royal Dutch Actuarial Association has estimated, in its
‘Projection Table 2016’, that the life expectancy of a girl
born in 2016 is 93.0 years and that of a boy born in 2016
90.1 years [1]. With a touch of optimism, these projections
may in fact be an underestimation, since much of the poten-
tial for prevention of cardiovascular disease is still waiting
to be used.
Consistently, the fall in cardiovascular mortality in west-
ern societies is explained as the consequence of primary
prevention, improved secondary prevention after a first
event, and improved acute and chronic therapy for clinical
events [2, 3]. For each of these elements, further improve-
ments may be expected, as illustrated this month in the
Netherlands Heart Journal.
In this issue, current patterns of care for patients with
ST-segment elevation myocardial infarction are highlighted
[4]. The creation of national databases is particularly help-
ful in benchmarking and identifying best practices. In ad-
dition, they provide opportunities for large-scale evaluation
of post-introduction changes in outcomes of interventions
[5]. Together, these will assist in further improvement of
clinical outcomes.
Large-scale implementation of simple and low-cost pre-
ventive therapies, such as statins, will have a major impact
on the burden of disease at a population level. Statins may
even provide better outcomes of acute therapies such as per-
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cutaneous coronary intervention. In this issue, an improve-
ment of post-procedural epicardial blood flow is described
in patients who are on statin therapy [6].
It is estimated that as much as 90% of the atheroscle-
rotic disease burden may be preventable, if modifiable risk
factors are adequately addressed [7]. Unfortunately, risk
assessment, individual counselling and initiation of med-
ication are all far from optimal today. An investigation of
the current state of secondary prevention in Amsterdam,
the Netherlands, is presented in this issue [8]. Only 4% of
patients with a self-reported previous cardiovascular event
had all risk factors on target. Adherence to drug therapy
is far from optimal, particularly in hypertension and dys-
lipidaemia, in spite of a wealth of evidence on the pow-
erful protection that it provides. Lifestyle improvements
(addressing smoking, obesity, sedentary behaviour) are dif-
ficult to accomplish and even more difficult to sustain. On
a societal level, education and infrastructural changes have
been modest at best.
Simultaneously, powerful new therapies for dyslipi-
daemia are under development, such as antibodies against
circulating proprotein convertase subtilisin/kexin type 9
(PCSK9). In this issue, a review is presented of current
and future options for the treatment of dyslipidaemia [9].
After this manuscript was accepted, on February 2nd, the
FOURIER trial (n = 27,000) was reported to show a signifi-
cant risk reduction with PCSK9 inhibition (by subcutaneous
evolocumab), on top of statin therapy. The main results of
this trial will be presented on Friday, March 17, at the
annual meeting of the American College of Cardiology in
Washington, DC. The Odyssey Outcomes trial (18,600 pa-
tients), that tests alirocumab in a comparable trial design,
is expected to finish by early 2018. Small interfering RNA
(siRNA) molecules directed against PCSK9 synthesis may
provide similar effects with less frequent dosing. However,
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these drugs are still in the early stages of development. Po-
tentially, even a vaccine may be developed against PCSK9.
Will a single injection early in life silence one of the most
important diseases we know?
Big questions lie ahead. With life span increasing, pre-
vention of cardiovascular disease in people above 75 years
of age will be less controversial than it is today. The costs
of the new classes of drugs may be prohibitive for large-
scale introduction. Globally, the burden of disease may in
fact increase in the coming decades, as a consequence of
changing lifestyles and the process of urbanisation. Oppo-
site trends in disease burden between affluent and devel-
oping countries would be unfortunate. Therefore, it is too
early to recline and celebrate. We may have won a few
battles, but the struggle continues.
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